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Abstract
Introduction: Nervous system injuries comprise a diverse group of disorders that include traumatic brain injury
(TBI). The potential of mesenchymal stem cells (MSCs) to differentiate into neural cell types has aroused hope for
the possible development of autologous therapies for central nervous system injury.
Methods: In this study we isolated and characterized a human peripheral blood derived (HPBD) MSC population
which we examined for neural lineage potential and ability to migrate in vitro and in vivo. HPBD CD133+, ATP-
binding cassette sub-family G member 2 (ABCG2)+, C-X-C chemokine receptor type 4 (CXCR4)+ MSCs were
differentiated after priming with b-mercaptoethanol (b-ME) combined with trans-retinoic acid (RA) and culture in
neural basal media containing basic fibroblast growth factor (FGF2) and epidermal growth factor (EGF) or co-
culture with neuronal cell lines. Differentiation efficiencies in vitro were determined using flow cytometry or
fluorescent microscopy of cytospins made of FACS sorted positive cells after staining for markers of immature or
mature neuronal lineages. RA-primed CD133+ABCG2+CXCR4+ human MSCs were transplanted into the lateral
ventricle of male Sprague-Dawley rats, 24 hours after sham or traumatic brain injury (TBI). All animals were
evaluated for spatial memory performance using the Morris Water Maze (MWM) Test. Histological examination of
sham or TBI brains was done to evaluate MSC survival, migration and differentiation into neural lineages. We also
examined induction of apoptosis at the injury site and production of MSC neuroprotective factors.
Results: CD133+ABCG2+CXCR4+ MSCs consistently expressed markers of neural lineage induction and were
positive for nestin, microtubule associated protein-1b (MAP-1b), tyrosine hydroxylase (TH), neuron specific nuclear
protein (NEUN) or type III beta-tubulin (Tuj1). Animals in the primed MSC treatment group exhibited MWM latency
results similar to the uninjured (sham) group with both groups showing improvements in latency. Histological
examination of brains of these animals showed that in uninjured animals the majority of MSCs were found in the
lateral ventricle, the site of transplantation, while in TBI rats MSCs were consistently found in locations near the
injury site. We found that levels of apoptosis were less in MSC treated rats and that MSCs could be shown to
produce neurotropic factors as early as 2 days following transplantation of cells. In TBI rats, at 1 and 3 months post
transplantation cells were generated which expressed markers of neural lineages including immature as well as
mature neurons.
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Conclusions: These results suggest that PBD CD133+ABCG2+CXCR4+ MSCs have the potential for development as
an autologous treatment for TBI and neurodegenerative disorders and that MSC derived cell products produced
immediately after transplantation may aid in reducing the immediate cognitive defects of TBI.
Introduction
Studies examining repair mechanisms in the brain have
shown that neural precursor cells have the capacity to
migrate to injury sites and differentiate into neurons [1-4].
Unfortunately, neurogenesis from endogenous stem cells
is not sufficient to produce meaningful levels of recovery
after injury [4,5]. Augmentation of endogenous stem cells
with cells from sources other than the brain may enhance
neurogenesis sufficiently to promote meaningful recovery.
Mesenchymal stem cells (MSC) have already been shown
to provide therapeutic benefits in animal models for a vari-
ety of neurological disorders including stroke, Parkinson’s
disease and traumatic brain injury (TBI) [6,7]. The poten-
tial of MSC to differentiate into neural cell types has
aroused hope for the possible development of autologous
therapies for central nervous system (CNS) injury for both
injured civilian and active duty military personnel [8]. Cur-
rent data have also suggested that MSC may also provide a
source for supportive factors that aid immune modulation
or neuro-protection, aiding in recovery [9]. Although MSC
have great potential, standard conditions for isolation
based on definitive sets of cell markers that relate to effi-
ciency of MSC to consistently develop into neural lineages,
have yet to be established. Thus, the inconsistent results of
some studies using MSC to treat neurological conditions
may be due in part to variations in culture conditions,
long-term passage of cells, or to the use of mixed popula-
tions of MSC at slightly different developmental stages.
Although few neuron-specific markers have been identi-
fied, early stem cell markers have been described that are
indicative of immature cell status. Such markers include
expression of CD133 [10,11], either alone [12], or in com-
bination with stage-specific embryonic antigen-4 (SSEA-4)
[13,14] or ATP-binding cassette sub-family G member 2
(ABCG2) [15]. Many of these markers have been used to
positively select for neural stem cells from fetal brain or
other tissue sources [12-17], yet few studies have focused
on neural differentiation of isolated MSC from non-mobi-
lized peripheral blood (PB) [18,19].
In this study we isolated and characterized a human PB-
derived (HPBD) MSC population, which we examined for
neural lineage potential and ability to migrate in vitro and
in vivo. We focused our attention on identifying MSC sub-
populations based on co-expression of the immature stem
cell markers CD133, SSEA-4, ABCG2 and chemokine
receptor type 4 (CXCR4), a molecule that has been shown
to be involved in stromal derived factor-1 (SDF-1)/
CXCR4-mediated migration and plays an important role
in the regulation of stem/progenitor cell trafficking
[20-23]. After sorting subpopulations based on expression
of immature stem cell markers we examined each sorted
population for their capability of neural marker induction
following trans-retinoic acid (RA) priming. We identified a
population of HPBD CD133+ABCG2+CXCR4+ MSC with
high neuronal marker induction efficiency. Transplanta-
tion of RA-primed CD133+ABCG2+CXCR4+ MSC into
the lateral ventricle of uninjured rats, or those subjected to
parasagittal fluid percussion TBI, resulted in survival of
cells, migration to the injury site, improvement in cogni-
tive functioning of TBI animals, differentiation of cells and
reduction in induction of apoptosis at the injury site after
transplantation. Transplanted MSC were shown to pro-
duce the neurotropic factors chondroitin sulfate proteogly-
can (CSPG) and brain derived neurotropic factor (BDNF).
The ability to obtain MSCs from an accessible source such
as PB makes them an excellent candidate for use as an




PB buffy coats were obtained from the Gulf Coast Blood
Bank or from volunteer donors (18 to 50 years of age).
PB was drawn from ten donors with informed consent
using University of Texas Institutional Review board
approved protocols. The mononuclear cell (MNC) frac-
tion was isolated using Ficoll density gradient separation
medium (GE Health Care-Biosciences, Pittsburg, PA,
USA). Subpopulations of MNC were isolated by counter-
current centrifugal elutriation using a Beckmann J6M
elutriator (Beckman-Coulter Instruments, Brea, CA USA)
in a Sanderson chamber. A Masterplex peristaltic pump
(Cole Parmer Instruments, Vernon Hills, IL, USA) was
used to provide the counter-current flow. RPMI 1640
supplemented with 2 mM glutamine, 100 units penicillin
G and 100 μg/ml streptomycin, and 10% donor-derived
autologous serum was used as elutriation medium. We
loaded 3 to 6 × 106 cells at 3000 RPM and elutriation
fractions were isolated using a stepwise reduction of
rotor speed and media flow to allow for collection of sub-
populations of MNC based on size and density. A 4- to 6-
μm cell fraction was collected and the phenotype of this
cell population was determined.
Cells were plated in 75- or 150-cm2 tissue culture flasks
in DMEM (Sigma, St Louis, MO, USA), 0.1 mM nones-
sential amino acids, 100-U/ml penicillin and streptomycin,
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and 1 ng/ml basic fibroblast growth factor (FGF) with 10%
fetal calf serum, plus 0.2 mM L-glutamine. The majority
of cells were found to be strongly adherent to plastic after
8 to 24 hours of culture.
Characterization of MSC
Antibodies for phenotyping conjugated to fluorescein iso-
thiocyanate (FITC), phycoerytherin (PE) or PerCP were
purchased from companies listed in Table 1 and were
used as described by each manufacturer. Corresponding
immunoglobulin (IgG)-matched isotype control antibodies
were used to set baseline values for analysis markers.
Staining for ABCG2 (Stem Cell Technologies, Vancouver,
Canada), CD133 (Miltenyi Biotech, Auburn, CA, USA),
CD105, CD90, CD29, and CXCR4 (BD Biosciences, San
Jose, CA, USA) was done with PE conjugated antibodies.
Elutriated MSC were stained in PBS (Ca- and Mg-free)
supplemented with 5% autologous serum. After the final
wash, cells were kept at 4°C in neurobasal media prior to
culture, or were fixed with 2% paraformaldehyde (PF)
before analysis using a FACSAria instrument (BD Bios-
ciences,), with acquisition and analysis using the FACS-
Diva program (BD Biosciences). Isolated cells expressed
MSC markers CD105, CD90, CD29 by flow cytometry and
were negative for expression of markers of hematopoietic
lineage, CD14, CD34, CD45 and Lineage-1 (Lin-1) as has
been previously described for bone marrow MSC [19].
Phagocytic capacity of elutriated cells was evaluated
using uptake of fluorescent beads as described previously
[24]. Selected elutriation fractions of cells were exposed
to 3.5 μg/ml lipopolysaccharide (LPS) (Sigma Aldrich), or
4 ug/ml phytohemagglutinin-M (PHAM), and superna-
tants were evaluated for cytokine production. The BD
Biosciences TH1/TH2 flow cyometric cytokine bead
array kit was used to measure IL-2, IL-4, IL-5, IL-10,
TNF and IFN-g protein levels produced by elutriated
cells pre- and post RA priming as well as post exposure
to LPS or PHAM as described by the manufacturer.
Induction of neuronal markers
Mononuclear cells (MNC) isolated from 10 blood donors
were subjected to counter-current centrifugal elutriation
and a 4- to 6-μm cell fraction was collected by elutriation
followed by fluorescence activated cell sorting (FACS)
based on co-expression of CXCR4 and CD133, CD133 and
ABCG2, or CD133 and ABCG2 and SSEA-4. MSC were
primed for induction of neural lineage markers by culture
in DMEM-LG supplemented with 10% human AB serum,
10-3 M b-mercaptoethanol (b-ME) (Sigma); 5 × 10-7 M
all-trans-retinoic acid (RA) (Sigma) for 24 hours [25-28].
Viability of cells was determined using a Molecular Probes
LIVE/DEAD Viability/Cytotoxicity Kit (Invitrogen,
San Jose, CA, USA). Cells were then cultured in neural
differentiation media (NDM) which was composed of neu-
robasal medium (Invitrogen, Carlsbad, CA, USA) with
addition of 2 mM L-glutamine, B-27 supplement (Invitro-
gen), 25 ng/ml FGF2, 10 ng/ml epidermal growth factor
(EGF), and 10% autologous or human AB serum.
Immunocytochemistry
Neural marker expression was examined using immu-
nostaining followed with evaluation by flow cytometry
and/or fluorescent microscopy. Neural markers that
were used to evaluate potential for neural marker
expression for selected subpopulations of the MSC
included microtubule associated protein-1 b (MAP-1b),
nestin, tyrosine hydroxylase (TH), type III beta-tubulin
(Tuj1), neuronal specific nuclear protein (NEUN), glial
fibrillary acidic protein (GFAP), choline acetyltransferase
(CHAT) enzyme and galactocerebroside (GalC) using
antibodies described below. Nestin was chosen because
it is expressed during neuronal development but is also
expressed in non-neural stem cell populations. MAP-1b,
although not restricted in expression to neuronal cells,
is present at high levels in the embryonic and newborn
rat brain and is an early neuronal microtubule-asso-
ciated protein that is involved in microtubule assembly.
TH is a 56 to 60 kD structural protein that is expressed
in the neurons of the peripheral nervous system (PNS)
and CNS, but is also expressed by non-neuronal tissues.
Tuj1 contributes to microtubule stability in neuronal
cell bodies and axons, and plays a role in axonal trans-
port. Antibodies against NEUN specifically recognize
the DNA-binding, neuron-specific protein, NEUN,
which is present in most CNS and PNS neuronal cell
types of most vertebrates. GFAP is an intermediate fila-
ment protein that is thought to be specific for astrocytes
in the CNS, and expression of this protein distinguishes
astrocytes from other glial cells. The neurotransmitter,
acetylcholine, is synthesized from choline and acetyl-
coA by the CHAT enzyme, making CHAT a specific
marker of cholinergic neurons. The regulation of CHAT
activity is thought to be important during the develop-
ment of nervous systems interactions. GalC is a specific
cell-surface antigenic marker for oligodendrocytes and
Schwann cells. GalC is also a major galactosphingolipid
of myelin, which plays a role in myelination.
Preparations for imaging were mounted in Slow Fade
GOLD with 4’,6-diamidino-2-phenylindole (DAPI) (Mole-
cular Probes, Eugene, OR, USA) and observed using an
LSM 510 Meta advanced laser scanning confocal micro-
scope (Zeiss, Thornwood, NY, USA). Fluorescent micro-
scopy was done using a Zeiss Axioscope Fluorescent
microscope or a Nikon T300 Inverted Fluorescent micro-
scope (Nikon Inc, Melville, NY, USA.). For brain sections,
all positive cells on a slide were counted. Three replicate
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Table 1 Classification of the 4 to 6 micron elutriated mononuclear cell fraction
Cell lineage marker Reagent
Source
Surface antigen RFI pre-priming, mean +/- SD (% positive) RFI Post priming, mean +/- SD (% positive)
Leukocyte BD CD45 (pan leukocyte) 6.3 +/- 1.1 (0%) 5.4 +/- 0.7 (0%)
BD CD14 (macrophage) 8.3 +/- 2.1 (0%) 6.2 +/- 1.4 (0%)
BD CD3 (T Cell) 5 +/- 0.2 (0%) 6.1+/- 1.6 (0%)
BD T cell receptor (T Cell) 6.3 +/- 1.4 (0%) 4.5 +/- 1.1 (0%)
BD CD19 (B cell) 6.8 +/- 0.7 (0%) 7.4 +/- 1.6 (0%)
BD Immunoglobulin (B Cell) 7.9 +/- 2.3 (0%) 7.6 +/- 3.1 (0%)
BD CD13 (myeloid lineage) 8 +/- 2.4 (0%) 5.5 +/- 2.1 (0%)
Endothelium BD CD31 5.9 +/- 2.2 (0%) 6.1 +/- 3.1 (0%)
Fibroblast BD CD104a 4.7 +/- 1.1 (0%) 5.1 +/- 2.4 (0%)
BD CD104b 6.2 +/- 2.4 (0%) 7.3 +/- 3.2 (0%)
Chemokine BD CXCR4 1236.2 +/- 362.2 (92.1 +/5.8%) 1422.1 +/- 303.2 (86.1 +/- 8.3%)
BD CXCR3 7.2 +/- 3.3 (0%) 6.2 +/- 2.7 (0%)
BD CCR5 8.2 +/- 3.2 (0%) 7.1 +/- 2.7 (0%)
Stem cell BD, CH SSEA-1 93 +/- 5.5 (35.2 +/- 5.2%) 5.4 2 +/-0.5 (5.4 +/- 1.6%)**
BD, CH SSEA-4 206.7 +/63 (41.5+/-6.9%) 5.39 +/- 0.7(0%)**
BD CD34 6.1 +/- 2.8 (0%) 7.2 +/- 3.4 (0%)
SCT ABCG2 670.9 +/- 38.7 (84.9 +/- 5.4%) 127.3 +/- 35.4 (31.5 +/- 5.7%)**
MIL, BD CD133 688.8 +/- 63 (95.1+/- 2%) 127.8 +/- 7.4 (39.2 +/- 7.8%)**
BD CD105 1892 +/- 49 (93& +/- 22) 855 +/- 34 (86 +/- 14%)*
BD CD90 1568 +/- 42 (96% +/- 54) 544 +/- 22 (74 +/-11)**
BD CD29 446 +/- 22 (85% +/-16%) 349 +/- 56 (61 +/- 22%)
Human Leukocyte Antigens BD MHC Class-1 (human) 38.6 +/- 8 (35+/- 6.2%) 59.5 +/-10 (59.4+/- 7.2%)
BD MHC Class II 11.3 +/- 3.79 (0%) 12.2 +/- 3.7 (0%)
Neuronal Markers CH Nestin 11.3 +/- 3.9 (0%) 143.7 +/- 42 (23.1 +/- 4.4%)*
CH Map-1B 11.3 +/- 3.9 (0%) 139.3 +/- 44. 2(16+/- 2.9%)*
CH, DAKO GFAP 4.2 +/- 1.6 (0%) 7.4 +/- 1.7 (0%)
CH Tuj1 2.6 +/- 1.1 (0%) 18.5 +/- 2.4 (3.4+/- 1.6%)
CH, CST TH 2.7 +/- 0.8(0%) 6.2 +/- 2.4 (2.1+/- 0.5%)
Immunocytochemistry was used to examine expression of hematopoietic-, fibroblast-, embryonic- or progenitor cell-associated cluster of differentiation (CD) antigens or markers indicative of neural lineage selection.
Staining was evaluated by quantitative flow cytometry using well-defined antibodies. This table shows the occurrence of positive cells (% of cells positive) and relative fluorescent intensity (RFI) of freshly isolated
cells before and after RA priming. Statistically significant comparisons for markers include those that decreased (*P < 0.0.001) and increased (**P < 0.05) between isolation and 24 hours post priming. MHC, major
histocompatibility complex; CXCR4, CXC chemokine Receptor-4; MAP-1b, microtubule associated protein-1; Tuj1, neuron specific class III b-tubulin; TH, tyrosine hydroxylase; SSEA-4, stage specific embryonic antigen;
















evaluations of cell counts for stained slides were per-
formed and averaged, and then counts were later checked
by a second observer.
In a subset of experiments cells were stained to identify
expression of neuroprotective products after 7 days of cell
culture. RA-primed or unprimed cells were stained for
expression of chondroitin sulfate proteoglycan (CSPG),
and brain derived neurotropic factor BDNF. For expres-
sion of CPSG by in vitro cultured MSCs, Alexa Fluor
Anti-chondroitin sulfate (BD Pharmingen) was used. For
identification of CSPG in brain sections anti-CPSG unla-
beled human specific antibody (EMD Millipore, MA,
USA) was used as described by the manufacturer. For
identification of expression of BDNF in cultured cells or
brain sections Anti-human Pro-BDNF (R & D Systems,
Minneapolis, Billerica, MN, USA) was used as described
by the manufacturer. Secondary antibodies used for
staining brain sections were conjugated to anti-mouse
rhodamine.
Flow cytometry
For flow cytometry, cells were fixed with 2% (w/v) PF
for 30 minutes at 37°C, washed in PBS and then per-
meabilized in 1% BD permeabilizing solution (BD Bios-
ciences) for 10 minutes with a final wash in tris buffered
saline (TBS). Nonspecific binding was blocked by a 1-
hour treatment in TBS plus 0.1% w/v Tween containing
defatted milk powder (30 mg ml-1). Cells were incubated
for 1 hour at 37°C with one of the following primary
antibodies (diluted in blocking buffer): nestin (EMD
Milipore, 1:200 dilution), CHAT (EMD Milipore, 1:250
dilution), GalC (EMD Milipore, 1:200 dilution), GFAP
(Dako, Glostrup, Denmark, 1:500 dilution), TH (Cell
Signaling Technologies, Danvers, MA, USA and EMD
Milipore, 1:200 dilution), Tuj1 (Eurogentec, Southamp-
ton, Hampshire, UK, 1:1,500 dilution), MAP-1 b (EMD
Milipore, 1:200 dilution) and SSEA-4 (EMD Milipore,
1:300 dilution). After three washes in TBS, cells were
incubated in secondary antibodies conjugated to FITC,
rhodamine, or Cy5 anti-mouse, anti-rat, or anti-rabbit
IgGs (1:500 dilution) for 1 hour at 37°C, washed then
stored at 4°C until analyzed. Use of isotype-matched
controls and omission of primary antibodies served as
negative controls and resulted in less than 2% back-
ground staining for flow cytometry analysis of samples.
Positive cells identified by expression of each marker,
or set of markers, were sorted using flow cytometry, and
cytospins of positively sorted cells were made and exam-
ined using fluorescent and confocal microscopy as
described above. To validate our immunostaining for
flow cytometric analysis we examined location of staining
or presence of appropriate staining patterns (intracellular,
nuclear or extracellular) of the cells on the cytospin
slides. For some phenotype evaluations we compared
manual counts of cytospin slides to the flow cytometric
data to make sure that we were analyzing whole cells and
not cell debris or damaged cells.
Immunoprecipitation
TH and nestin production was also shown by immunopre-
cipitation of these proteins followed by gel electrophoresis.
CD133+ABCG2+CXCR4+ cells were incubated for
6 hours in 0.5 mCi of 35S-methionine (GE Healthcare
Biosciences)in 2 ml of methionine-free DMEM (MP
Biomedicals, Irvine CA, USA) and then cells were lysed
using 1% NP-40 in 50 mM Tris-HCL with 150 mM NaCl,
pH 8, buffer. For immunoprecipitation of newly produced
neuronal proteins 10 μg of antibody was added to 50 μl of
35S methionine labeled and pre-cleared lysate and was
incubated at 4°C for 1 hour [29]. After washing, 50 μl of
protein A slurry in pre-chilled lysis buffer was added and
the sample was incubated for 1 hour at 4°C. After the last
wash, the sample supernatant was aspirated and 50 μl of
1× Laemmli sample buffer was added to each bead pellet.
Samples were vortexed and heated to 90 to 100°C for
10 minutes. Samples and MW standards with known
concentrations were separated by electrophoresis. Autora-
diography was used to evaluate protein bands.
Evaluation of micro-environmental cues on in vitro
induction of neuronal markers
1 × 105 unprimed or RA-primed CD133+ABCG2+CXCR4
+ MSC were FACS-sorted and placed in the bottom of a
transwell plate with a 0.2 um filter; 1 × 106 cells from four
different neuronal cell lines or from a bone marrow stro-
mal cell line (lines purchased from American Type
Culture Collection, ATCC, Manassas, VA, USA) were
placed in the top chamber. Cell lines used included
human astroglial cell line (SVG p12), rat astrocyte line
(DITNC 1), human neuroblastoma line (SK-N-FI), human
dopaminergic line (SK-N-MC), and a human bone mar-
row stromal cell line (HS-5). After 7 days of culture, the
CD133+ABCG2+CXCR4+ MSC efficiency of neuronal
lineage differentiation was evaluated by staining for
expression of nestin, GFAP, CHAT, TH, Tuj1 or GALC
with analysis by FACS. The cells that were positive for
expression of nestin, GFAP, CHAT, TH, Tuj1, or GALC
were sorted and examined using fluorescent microscopy.
Cytospin preparations were performed as described by the
manufacturer (Shandon, Pittsburg, PA, USA). In a subset
of experiments (n = 8) in order to evaluate the antibodies
chosen for neuronal marker analysis, MSC were cultured
for 7 days, cytospins of cells were made, slides were fixed
in 2% freshly made PF and were then stained for expres-
sion of neuronal markers.
To observe the influence of direct cell-to-cell interac-
tions on differentiation, we placed 1 × 105 unprimed or
RA-primed CD133+ABCG2+CXCR4+ MSC in co-culture
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with 1 × 106 carboxyfluorescein diacetate sucinimydyl
ester (CFSE)-labeled cell lines listed above following man-
ufacturer’s instructions (Molecular Probes,). After 7 days
of culture, efficiency of neuronal lineage differentiation
was evaluated with analysis using flow cytometry by gating
on the CFSE-negative MSC.
Examination of DNA ploidy and cell fusion
DNA content per cell was determined by FACS analysis
after staining the cells with propidium iodide (PI). After
co-culture, cells were fixed with 70% ethanol, at 4°C for 16
hours. The cells were then stained with PI (400 ug ml-1;
Sigma) just before FACS analysis. To ensure that our
results were due to differentiation and not fusion of MSC
with mature neurons, we analyzed the DNA content of
unprimed and primed MSC before and after co-culture
with mature neuronal cell lines. In all cases we did not see
an increase in ploidy, suggesting that the majority of the
cells were diploid and few cells were polyploid (< 2%). We
also did not see any signs of cell fusion in the cells (after
staining with DAPI) in any of the co-culture experiments
nor in confocal analysis of the cells after transplantation in
the brains of uninjured or TBI rats.
MSC migration capability
To examine migration functionality of CXCR4 on the
CD133+ABCG2+ MSC subpopulation, migration capabil-
ity of these cells and the unsorted CXCR4 subpopulation
was examined in response to SDF-1. For these experi-
ments 1 × 105 elutriated but unsorted MSC, unprimed, or
RA-primed CD133+ABCG2+CXCR4+ MSC were isolated
from 10 blood donors. Cells were untreated, pretreated
with 5 μg/ml of dexamethasone, or treated with a CXCR4
blocking antibody (Clone 44708, 10 μg/ml, R & D systems
or BD) and were placed in serum-free neural basal med-
ium without growth factors in the top chamber of a
Transwell plate (Corning Life Sciences, Lowell, MA, USA)
with a 5 μm pore-sized filter. A time course of migration
was done in order to determine that the optimal incuba-
tion time for this assay was four hours. Lower chambers of
the transwell were filled with neural basal medium con-
taining SDF-1 (200 ng/ml), homogenates made from unin-
jured rat brains, TBI brain homogenate, or medium alone.
Plates were incubated at 37°C, 95% humidity and 5% CO2
for 4 hours then cells from both chambers were collected
and counted using a Multisizer 3 coulter counter (Beck-
man-Coulter). Results are presented as an average chemo-
tactic index (the ratio of cells moving towards SDF-1 to
the number of cells moving towards media alone) for cells
isolated from 10 blood donors.
Fluid percussion injury
Animal procedures and surgeries were approved by
the Institutional Animal Care and Use Committee of the
University of Texas Medical Branch at Galveston and were
performed under aseptic conditions in compliance with
NIH Guide for Care and Use of Laboratory Animals. Non-
immune-suppressed, adult, male Sprague-Dawley rats
weighing 350 to 400 grams were anesthetized with isoflur-
ane in an anesthetic chamber, intubated, and mechanically
ventilated with 1.5 to 2.0% isoflurane in O2:room air
(70:30) using a volume ventilator (EDCO Scientific, Chapel
Hill, NC, USA). Rats were anesthetized and prepared for
parasagittal fluid-percussion TBI as previously described
[30-32]. Briefly, rats were placed in a stereotaxic frame
and the scalp was sagittally incised. A 4.0 mm-diameter
hole was trephined into the skull 2.0 mm to the right of
the midsagittal suture and midway between the lambda
and bregma. A modified Luerlok syringe hub was placed
over the exposed dura, bonded in place with cyanoacrylic
adhesive and covered with dental acrylic. Rats were con-
nected to the trauma device, anesthesia was shut off and
animals were subjected to moderate (2.0 ± 0.1 atm) injury.
After TBI rats were disconnected from the fluid percus-
sion device and righting reflex was assessed every 60
seconds until a normal righting reflex was observed. Rats
were then again placed on 1.5% isoflurane, wound sites
were treated with a topical antibiotic, infused with bupivi-
caine and sutured. Isoflurane was discontinued and the
rats were extubated and allowed to recover in a warm,
humidified incubator.
Preparation of MSC for transplantation
CD133+ABCG2+CXCR4+ MSC were primed with RA for
24 hours before transplantation. Immediately prior to
transplantation, unprimed or RA-primed CD133+ABCG2
+CXCR4+ MSC were labeled with CFSE to allow for track-
ing of cells and estimation of MSC proliferation as
described previously [33]. CFSE allows for tracking of stem
cells after in vivo administration; 5-bromo-2-deoxyuridine
(BRDU) was not used to label cells since BRDU has been
shown to induce senescence [34] or be selectively toxic to
MSC [35]. In a subset of experiments non-CFSE-tagged
MSC were transplanted into rats used to evaluate induc-
tion of apoptosis following injury.
One day post-TBI, all animals were anesthetized with
isoflurane. We used 15% Pluronic F-127 (PF-127) in
DMEM as a vehicle to aid transplantation of 5 × 105
CFSE-labeled, unprimed or RA-primed CD133+ABCG2
+CXCR4+ MSC, which were injected into the lateral
ventricle using a 5-μl Hamilton syringe with a 26-gauge
needle. Sham-injured animals underwent needle inser-
tion and injection of PF-127 vehicle alone, or received 5
× 105 CFSE-labeled, unprimed or RA-primed CD133
+ABCG2+CXCR4+ MSC, into the lateral ventricle. Ani-
mals were observed for any signs of rejection or infec-
tion until sacrificed.
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Morris water maze
The procedures for assessing spatial memory perfor-
mance using the Morris Water Maze (MWM) are
described in detail elsewhere [36]. Briefly, the MWM is
a black tank (180 cm diameter, 28 cm depth) filled with
water. A clear, Plexiglas platform was hidden beneath
the surface of the water. When released, the animal
swims around the pool in search of a platform. The ear-
liest and classic measure of learning in the MWM is
latency, which is the time it takes for an animal to find
the platform. Beginning on post-injury day 11 (PID 11),
rats were tested with four trials per day for five days.
For each trial, the rat was placed in the tank facing the
wall and was allowed to swim for up to 120 sec to find
the hidden platform. If the rat failed to find the platform
after 120 sec, it was placed on the platform by the
experimenter. All rats were allowed to remain on the
platform for 30 sec before being placed in a heated
incubator for a four-minute rest period between trials.
For the next three trials, the procedures were the same
except that the rat was placed in a different quadrant of
the pool. The location of the platform remained the
same. After the last trial on PID 11, the platform was
extended to be visible above the surface of the water.
The visible platform task serves as a control for poten-
tial non-specific deficits in visual and motor function.
Finally, after the last trial on the last testing day (PID
15), a single probe trial was performed. The platform
was removed and the percent time in the platform
quadrant was measured. Swim speed, time to find the
platform and other variables were measured using a
video tracking system. Normal rats will swim to the
target quadrant of the pool, which is considered a good
test, and TBI rats do poorly in this test and do not
swim to the target quadrant. Following MWM testing
animals were sacrificed, and their brains were removed
and prepared for assessment of stem cell migration, dif-
ferentiation and induction of apoptosis.
Histological evaluation
Animals were anesthetized and sacrificed at 2 days, one
month or three months after the administration of moder-
ate TBI, as described in Table 2, using standard guillotine
techniques. Brains were removed and fixed in 4% PF for
12 hours, embedded in paraffin or were frozen for later
histological examination. Intact brains were cut in half and
were then frozen in tissue freezing medium (Triangle
Biomedical Sciences, Durham, NC, USA) prior to being
serially sectioned on a Microm cryomicrotome (Thermo
Scientific, Walsdorf, Germany). For determinations of
transplanted cell survival each slide was scored by count-
ing the total number of CFSE-positive cells in serial sec-
tions of brains from either uninjured or TBI rats that had
received CFSE-labeled RA-primed or unprimed CD133
+ABCG2+CXCR4+ MSC. CFSE-positive cells (green) were
counted under 400× magnification. Sections from unin-
jured or TBI rat brains that contained CFSE-positive cells
were also stained for expression of Tuj1 or NEUN. All
Tuj1- and NEUN-positive cells (red) were also counted on
each slide under 400× magnification. Three replicate mea-
surements of slides were performed by the same observer
for each slide. All slides were counted without knowledge
of the neuronal or cell-specific marker being examined,
and results were confirmed through a second reading by









Sham injury No mesenchymal stem cells
(MSC)
8 8 1 month (4) 8
3 months (4)
Sham Injury Primed MSC 4 Not tested 2 days (4) 4
Traumatic brain injury
(TBI)
No MSC 8 8 1 month (4) 8
3 months (4)
TBI No MSC 4 Not tested 2 days (4) 4
TBI Unprimed MSC 8 8 1 month (4) 8
3 months (4)
TBI Unprimed MSC 4 Not tested 2 days (4) 4
TBI Primed MSC 8 8 1 month (4) 8
3 months (4)
TBI Primed MSC 4 Not tested 2 days (4) 4
A total of 48 male Sprague-Dawley rats were randomly divided into injury or treatment groups; 12 rats were sham-injured and of these animals, 8 received no
stem cell treatment and 4 received RA-primed MSC: 36 rats were subjected to moderate TBI and of these animals 12 were untreated, 12 were treated with
unprimed MSC and 12 were treated with RA-primed MSC. Eight animals were randomly selected from each of these groups (sham injury, TBI, TBI with unprimed
MSC, TBI treated with primed MSC) for Morris water maze (MWM) evaluation and 4 rats from this and other groups were euthanized for histological evaluations
alone.
Nichols et al. Stem Cell Research & Therapy 2013, 4:3
http://stemcellres.com/content/4/1/3
Page 7 of 23
another person. The inter-observer agreement percentage
for these cell counts was calculated and recorded.
Apoptosis was measured in sections of brains from sham,
TBI and TBI plus MSC-treated animals one month follow-
ing injury. Apoptosis was determined by quantitation of
DNA strand breaks using the terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) method for
detecting DNA fragmentation (In Situ Cell Death Kit;
Boehringer Mannheim) as described in the manufacturer’s
instructions. Frozen sections (5 to 7 μm) were examined
for cell migration, survival and engraftment or were stained
to evaluate expression of GFAP, TH, CHAT, GalC, Tuj1
and CXCR4 and human major histocompatibility molecule
(MHC) class I or MHC class II (MHC II). Brain sections
were also stained for the production of SDF-1 or the neu-
roprotective factors chondroitin sulfate proteoglycans
(CSPGs) and BDNF.
Statistical analysis
For cell phenotype analysis in Table 1, 10,000 cells were
collected for each flow cytometry sample examined (RA-
primed or unprimed). For all other data comparisons the
paired samples t-test was used to compare means for 10
blood donors. Statistical analyses for these data were per-
formed using GraphPad InSTAT software (version 2003).
Mean values and SD are reported. Mean differences in the
values were considered significant when P was < 0.05.
MWM latency data were analyzed using analysis of var-
iance for a two-factor experiment with repeated measures
on time. The two factors were treatment group (4 groups)
and day (5 days). Data analysis was carried out using
PROC MIXED, the SAS® system, release 9.1 [37], with the
first order autoregressive option for covariance structure.
The main effects and the interaction were tested at the
0.05 experimental-wise error rate. Multiple comparisons
were conducted using Fisher’s least significant difference
procedure with Bonferroni adjustment for the number of
comparisons.
Results
MSC in human PB were identified by isolating small cell
fractions of human MNC using counter-current centri-
fugal elutriation. Characterization of a 4 to 6 μm-sized
elutriation fraction showed that these cells were CD105
+CD90+CD29+ MSC. Subpopulations of cells were
found that coexpressed CD133, ABCG2, SSEA-4 and
CXCR4 (Table 1). Evaluation of the cells immediately
after isolation and at 24 hours post RA priming using
flow cytometry suggested that they were not of leuko-
cyte, fibroblast, endothelial or hematopoietic stem cell
lineages (Table 1). The cells were Lin-1- and CD14-
negative and were not capable of phagocytosis or cyto-
kine production prior to or after priming, or after
stimulation with LPS or PHAM, which was not true for
other elutriation fractions containing leukocytes isolated
from the same donor (data not shown). These PB-
derived MSC continued to express CXCR4 24 hours
after priming, expressed low levels of human major
histocompatibility complex class I (MHC I), human
leukocyte antigen (HLA) A, B and C, and were negative
for MHC class II (DR, DQ, DP) (Table I).
Freshly elutriated cells did not express any neuronal
lineage markers at the time of isolation (Table 1). While
expression of CXCR4 remained relatively unchanged 24
hours after priming, expression of CD133, ABCG2 and
SSEA-4 on MSC were significantly reduced (Table 1).
An example of a sort gate used for isolation of CXCR4
+CD133+ABCG2+ subpopulations is shown in Figure
1A. After elutriation, the cells were round and uniform
in shape (Figure 1B). Twenty-four hours after RA prim-
ing in culture, the cells were strongly adherent to plastic
and were spindle shaped with numerous cell processes
(Figure 1C). The CD133+ABCG2+CXCR4+ MSC subpo-
pulation, which was isolated from nonmobilized human
PB, formed neurospheres (data not shown).
Representative flow cytometry histograms showing
staining controls (Figure 1D), expression of nestin (Figure
1E) and MAP-1b (Figure 1F) pre- and post RA priming as
well as confocal images of purified control, nestin or
MAP-1b-positive subpopulations (Figure 1G-I) are shown.
RA-primed MSC expressed nestin (Table 1, Figure 1E and
1H) and MAP-1b (Table 1, Figure 1F and 1II) after 24
hours of culture, while unprimed cells remained undiffer-
entiated. Both the nestin-positive and MAP-1b subpo
pulations continued to express CXCR4 24 hours post
priming. We also examined nestin production at 24 hours
and TH production at 7 days in primed subpopulations of
unsorted MSC or subpopulations that were isolated based
on co-expression of CD133, CD133 & ABCG2 or CD133
& ABCG2 & SSEA-4 combined with expression of
CXCR4 (Figure 1J). The highest efficiency of nestin and
TH production was in a CD133+ABCG2+SSEA-4
+CXCR4+ subpopulation (Figure 1J). The average number
of CD133+ABCG2+SSEA-4+CXCR4+ MSC isolated from
10 donors was 0.59 per ul of PB and ranged from 12,339
to 32,667 cells isolated per unit of PB (450 ml). Although
the CD133+ABCG2+SSEA-4+CXCR4+ MSC subpopula-
tion was induced to express neuronal markers more
efficiently, fewer cells with this phenotype could be consis-
tently isolated, making this population a less favorable
candidate for use in our in vivo transplantation studies
(Figure 2A). Since our goal was to evaluate the capability
of selected subpopulations of CD133+ MSC to differenti-
ate into neural lineages in vitro and in vivo, our experi-
ments were done using a CD133+ABCG2+CXCR4+ MSC
subpopulation.
CD133+ABCG2+CXCR4+ MSC isolated from most
donors expressed nestin by 24 hours and TH by 7 days
Nichols et al. Stem Cell Research & Therapy 2013, 4:3
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Figure 1 Isolation of mesenchymal stem cells (MSC) and subpopulations. (A) Representative dot plot for the sorting gate used in collection of
CD133+ABCG2+CXCR4+ MSC. (B) Phase contrast micrograph of freshly isolated CD133+ABCG2+CXCR4+ MSC prior to, as well as (C) 24 hours post
trans-retinoic acid (RA) priming. (D-F) A representative set of histograms showing flow cytometry evaluation of nestin and microtubule associated
protein (MAP)-1b expression by unprimed or RA-primed CD133+ABCG2+CXCR4+ MSC from one donor; 10,000 cells were collected for each flow
cytometry sample. (G-I) Representative confocal images of CD133+ABCG2+CXCR4+ MSC showing expression of nestin and MAP-1b at 24 hours. (G)
Unprimed MSC. (H and I) RA-primed MSC; (H) sample stained for expression of CXCR4 (red) and nestin (green); (I) cells showing expression of CXCR4
(red) and MAP-1b (green). (G) H and I staining control. (J) MSC subpopulations were elutriated or sorted by fluorescence-activated cell sorting (FACS)
based on co-expression of CD133 and CXCR4, CD133 and ABCG2 and CXCR4, or CD133 and ABCG2 and SSEA-4 and CXCR4. Data are for MSC
subpopulations isolated from 10 blood donors. Results represent the average +/- SD. Statistically significant comparisons (*P < 0.05, **P < 0.005) for
nestin and tyrosine hydroxylase (TH) production for elutriated but unsorted cells compared to each subpopulation of FACS-sorted MSC are shown.
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Figure 2 MSC subpopulation isolation and induction of neural markers. (A) Number of cells per μl isolated from peripheral blood (PB) for
the CD133 and CXCR4, CD133 and ABCG2 and CXCR4, or CD133 and ABCG2 and SSEA-4 and CXCR4 subpopulations. Data are from 10 PB
donors. Results represent the average +/- SD. Statistically significant comparisons (*P < 0.05, **P < 0.005) for the CD133 and CXCR4, or CD133
and ABCG2 and CXCR4 or CD133 and ABCG2 and SSEA-4 and CXCR4 subpopulations. (B) Representative histograms showing evaluation of
CXCR4+CD133+ ABCG2+ MSC differentiation for cells isolated from one donor, pre-priming as well as 24 hours or 7 days post-RA priming; (B)
isotype staining control, (C) expression of nestin, (D) expression of TH: 10,000 cells were collected for each sample. (E) Immunoprecipitation of
newly produced 35S methionine-labeled nestin or tyrosine hydroxylase (Ty Hyd) from cells isolated from two donors (A and B); MW, molecular
weight. (F) Evaluation of viability of primed or unprimed MSC isolated from 10 donors after 24 hours, 3 days (D3), or 7 (D7) days of culture.
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(Figure 2C and 2D) although there were occasionally dif-
ferences in the kinetics of expression of these proteins in
cells isolated from different donors (Figure 2E). Examina-
tion of viability of unprimed and RA-primed CD133
+ABCG2+CXCR4+ MSC indicated that similar levels of
cell death occurred over 7 days of culture (Figure 2F). To
determine the range of neural markers induced after 7
days of in vitro culture of CD133+ABCG2+CXCR4+ MSC
in neural differentiation media, staining was performed to
evaluate nestin (Figure 3A), GFAP (Figure 3B), TH and
co-expression of Tuj1, nestin and NEUN (Figure 3C),
Tuj1 (Figure 3D), CHAT (Figure 3E) and GalC (Figure
3F). Unprimed CD133+ABCG2+CXCR4+ MSC remained
unchanged in morphology after 7 days of culture and did
not express mature neuronal markers (Figure 3A-F and
3G). Primed CD133+ABCG2+ CXCR4+ MSC became
extremely elongated and produced multiple cell processes
(Figure 3A-D). After 7 days of culture, less than 3.5% of
unprimed MSC spontaneously expressed mature neural
markers, but RA-primed CD133+ABCG2+CXCR4+ MSC
consistently showed increased TH (45.2 +/- 9.7%), Tuj1
(35.23 +/-7.9%) and NEUN (28.2 +/-.11.1%) (Figure 3G).
Expression of GFAP was low in these experiments (4.88
+/- 2.4%) and was slightly higher than for unprimed MSC
(3.49+/- 0.7%). CHAT and GalC expression were the same
as background levels of the unprimed MSC subpopulation
(< 3%) (Figure 3E-G).
Co-culture experiments
For co-culture experiments allowing direct cell to cell con-
tact, neuronal cell lines were labeled with CFSE prior to
addition to the culture of unlabeled, unprimed or RA-
primed CD133+ABCG2+CXCR4+ MSC. Analysis was
done by gating on the CFSE-negative CD133+ABCG2
+CXCR4+ MSC population and sorting the MSC prior to
staining for expression of mature neuronal markers. Flow
cytometry analysis for a representative co-culture experi-
ment allowing cell contact between RA-primed MSC and
the CFSE-labeled rat astrocye cell line, DITNCI, is shown
in Figure 4A. In this experiment TH was induced in 81.1%
of the primed MSC after 7 days (Figure 4A) in the absence
of cell fusion with pre-existing mature neuronal cells.
Only 0.6% of primed CD133+ABCG2+CXCR4+ MSC
were induced to express TH after co-culture with the
bone marrow stromal line (HS-5) (Figure 4B). Isotype con-
trol staining was 2% +/- 0.92 or less for both cultures and
is shown as the green plot overlay (Figure 4A and 4B).
Direct contact co-culture with human astroglial (SVGp12)
cells induced high levels of expression of TH as did
co-culture with rat astrocyte (DITNC 1) cells and dopami-
nanergic (SK-N-MC) cells (Figure 4C), but induced lower
levels of other neural markers (Figure 4C, top graph).
When CD133+ABCG2+CXCR4+ MSC were cultured
in transwells that did not allow cell to cell contact the
highest levels of neural marker induction also occurred
when MSC were cultured with human astroglial
(SVGp12) cells, which induced high levels of expression
of TH as did co-culture with rat astrocyte (DITNC 1) or
the neuroblastoma line (SK-N-FI) (Figure 4C, bottom
graph). Differentiation efficiency of cells in transwell cul-
tures was much lower than that of cells with direct con-
tact. Neither unprimed CD133+ABCG2+CXCR4+ MSC
nor RA-primed MSC cultured with the bone marrow
stromal line HS-5 induced production of the neuronal
markers when directly cultured with MSC or in trans-
well culture allowing no direct cell to cell contact (Fig-
ure 4C). To ensure that our results were due to
differentiation, and not to fusion of CD133+ABCG2
+CXCR4+ MSC with mature neurons we analyzed the
DNA content of unprimed and RA-primed MSC before
and after co-culture with mature neuronal cell lines. In
all cases we did not see an increase in ploidy suggesting
that the majority of the cells were diploid and few cells
were polyploid (< 2%). We also did not see any signs of
cell fusion (after staining with DAPI) in any of the co-
culture experiments, nor in confocal analysis of the cells
after transplantation into the brains of uninjured or TBI
rats.
Chemotaxis assay
Success of a cell therapy depends on sufficient recruitment
of applied cells to the injury site or target tissue. Unprimed
and RA-primed CD133+ABCG2+CXCR4+ MSC could be
shown to migrate in response to SDF-1 in transwell migra-
tion assays (Figure 5A). Dexamethasone treatment of
unprimed and RA-primed CD133+ABCG2+CXCR4+
MSC reduced CXCR4 expression and subsequent migra-
tion of these cells in vitro (Figure 5A and 5B, red,
dexamethasone-treated; green, untreated). Migration in
these assays was also reduced after anti-CXCR4 antibody
treatment. RA-primed CD133+ABCG2+CXCR4+ MSC
migrated in response to homogenized brains of TBI rats
but not in response to homogenized brains from uninjured
rats (Figure 5A) and migration in response to TBI brain
homogenate could be blocked by addition of anti-CXCR-4
antibody (P = 6.5 × 10-6) supporting a CXCR4-mediated
mechanism of cell migration for this cell subpopulation.
Elutriated but unsorted CXCR4+ MSC were also shown to
migrate in response to SDF-1 (Figure 5A) and the migra-
tion of this cell population was also blocked using
anti-CXCR4 blocking antibody (Figure 5A and 5B).
The injury site and areas corresponding to the loca-
tion of the tissue sections are shown in Figure 5C.
Following in vivo transplantation of CD133+ABCG2
+CXCR4+ MSC into the lateral ventricle of uninjured
and TBI animals, brain sections were stained for the
presence of SDF-1 (Figure 5D-F and 5I). Sections of
brains from uninjured animals did not show staining for
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Figure 3 Induction of neural markers in vitro. Representative confocal images of unprimed and trans-retinoic acid (RA)-primed fluorescence-
activated cell sorting (FACS)-sorted CD133+ABCG2+CXCR4+ MSC showing expression of (A) nestin (red), (B) glial fibrillary acidic protein (GFAP)
(green), (C) nestin (green), neuronal specific class III b-tubulin (Tuj1) (red) and neuron specific nuclear protein (NEUN) (teal nuclei, white arrow),
(D)Tuj1 (green). For RA-primed MSC anticholine acetyl transferase (CHAT) and galactocerebroside (GalC) levels were similar to unprimed MSC.
Diamidino-2-phenylindole (DAPI) nuclear stain (blue) was used in all preparations. (G) Efficiency of neuronal lineage marker expression as
evaluated by flow cytometry of RA-primed MSC (solid black bars) after 7 days of culture to evaluate nestin, GFAP, CHAT, Tuj1, TH, GalC and
NEUN by CD133+ABCG2+CXCR4+ MSC isolated from 10 donors, and cultured in neural differentiation media. Results represent the average +/-
SD. Statistically significant comparisons indicated by brackets (*P < 0.05, **P < 0.005).
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Figure 4 Microenvironmental cues and neuronal marker expression. (A) Flow cytometry histograms showing neuronal marker expression by
trans-retinoic acid (RA)-primed CD133+ABCG2+CXCR4+ MSC after co-culture allowing direct cell to cell contact with the rat astrocyte cell line
(DITNC1). (B) Co-culture of RA-primed CD133+ABCG2+CXCR4+ MSC allowing cell to cell contact with human bone marrow cell line (HS-5). Isotype
staining control for each is shown as a green overlay histogram. Control levels for all samples were ≤ 2% cells positive. (C) RA-primed CD133+ABCG2
+CXCR4+ MSC were cultured allowing cell to cell contact (top graph) or no contact (bottom graph) with human astroglial (SVGp12), human
neuroblastoma (SK-N-F1), rat astrocyte (DITNC1), human dopaminergic (SK-N-MC) cell line or, as a control, HS-5. Efficiency of neuronal marker
expression after 7 days of culture for nestin, glial fibrillary acidic protein (GFA), anticholine acetyl transferase (CHAT), tyrosine hydroxylase (TH), type III
beta tubulin (Tuj1) and galactocerebroside (GalC) production is shown. Results represent the average +/- SD for 10 donors. Statistically significant
comparisons (*P < 0.05, **P < 0.005) are indicated for each marker compared to control cells, which were RA-primed but not cultured with any of the
cell lines listed. Unprimed cells expressed < 2% positive cells when cultured with mature neural cells for all of the mature neuronal markers evaluated.
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Figure 5 Migration capacity of mesenchymal stem cells (MSC). (A) Evaluation of the migration ability of CD133+ABCG2+CXCR4+ MSC.
Results are presented as a chemotactic index (the ratio of cells moving towards stromal cell-derived factor-1 (SDF-1) or tissue homogenates
compared to the number of cells moving towards media alone). Untreated (UNTR.), dexamethasone-treated (DEX TR.) and CXCR4 antibody-
treated (ANTI-CXCR4 TR.) Trans-retinoic acid (RA)-primed MSC were evaluated for their ability to migrate. Migration of this cell population was
also evaluated in response to uninjured (Uninj.) or injured (TBI) brain homogenates (Br. Homog.) alone or brain homogenate after treatment of
MSC with anti-CXCR4 blocking antibody. Results for the migration of elutriated but unsorted MSC with and without treatment with anti-CXCR4
blocking antibody are also shown. Results represent the average +/- SD in the chemotactic index for 10 blood donors. Statistically significant
comparisons are indicated in brackets (*P < 0.05, **P < 0.005). (B) Evaluation of CXCR4 expression before (green histogram) and after
dexamethasone treatment of MSC (red histogram) using quantitative flow cytometry. (C) Schematic showing both the injury site (black arrow)
and general regions evaluated in both uninjured and TBI rats shown in D-I (red circle). (D, E, F) Production of SDF-1 in (D) uninjured rat, (E) TBI
rat at 2 days and (F) at 1 month post injury. Arrow points to positive staining for SDF-1 in a micro-vessel in the brain 2 days after transplantation
of MSC. (G) Schematic showing both the injury site (black arrow) and general regions evaluated in both H and I. (H) Migration of CFSE+ CD133
+ABCG2+CXCR4+ MSC. Carboxyfluorescein succinimidyl ester (CFSE)-labeled cells, green, (white arrow injury site) and (I) production of SDF-1
(red) in TBI rats as well as presence of CFSE-labeled MSC after 1 month; (D-I) 4’,6-diamidino-2-phenylindole (DAPI) blue nuclei.
Nichols et al. Stem Cell Research & Therapy 2013, 4:3
http://stemcellres.com/content/4/1/3
Page 14 of 23
SDF-1 and few CFSE+ cells were found to have
migrated to the regions corresponding to the injury site
in these animals (Figure 5D). Sections of brains from
TBI rats show the presence of high levels of SDF-1 (Fig-
ure 5E, F and 5I) at the injury site and numerous CFSE
+ cells were seen to have migrated into these high-SDF-
1 + areas (Figure 5H and 5I).
MWM latency results
Interaction of treatment group by day was not statisti-
cally significant. That is, treatment group differences did
not statistically significantly fluctuate from day to day,
or they remained the same from day to day (Figure 6).
Overall (across all time points) latency of the TBI-alone
group and the TBI+ unprimed MSC group were not sta-
tistically significantly different. That is, unprimed MSC
did not significantly improve the overall latency after
TBI and remained at the level of the TBI-alone group.
Overall latency of the TBI primed MSC group and unin-
jured group were not significantly different. That is,
primed MSC after TBI improved the latency to the level
of the uninjured group. For overall latency, there were
differences between the TBI-alone and the uninjured
group, and between the TBI+ unprimed MSC and TBI+
primed MSC groups, although these were not statisti-
cally significant. Overall (across the four treatment
groups) latency at day 12 was statistically significantly
improved from day 11. Similarly, overall latency at day
13 was significantly improved from day 12. Overall
latency from day 13 to day 14, and also day 14 to day
15 continued to improve, although this was not statisti-
cally significant.
Histological examination at 2 days or 1 month post
transplantation
CD133+ABCG2+CXCR4+ MSC were held at 4°C for 2
hours prior to transplantation. Viability of MSC at 4°C
in 15% PF-127 in DMEM was consistently better than
in PBS (Figure 7A), and because of this 15% PF-127 in
DMEM was used as a vehicle for transplantation. CFSE-
labeled MSC were placed in the lateral ventricle (Figure
7B, black arrow injury site). In uninjured rats one
month after transplantation of CD133+ABCG2+ CXCR4
+ MSC only a small fraction of RA-primed MSC
migrated out of the ventricle into regions such as the
cortex and hippocampus (Figure 7C). Most MSC in the
ventricle were amoeboid in shape and expressed CXCR4
(Figure 7C and 7D). As early as 2 days post transplanta-
tion in rats subjected to TBI, more cells were seen to
have migrated out of the ventricle than had occurred in
uninjured rats by 1 month (Figure 7C compared to 7D).
In TBI rats sacrificed after one month few CD133
+ABCG2+ CXCR4+ MSC remained in the lateral ventri-
cle, and the majority of these cells moved to regions
Figure 6 Morris water maze (MWM) test. (A) Time to find a hidden platform in the MWM (latency) in rats subjected to no injury (sham) or
moderate traumatic brain injury (moderate TBI) alone, or TBI followed by transplantation with unprimed (UPR) or trans-retinoic acid (RA)-primed
(PR) CD133+ABCG2+CXCR4+ MSC. Latency of the TBI-alone and TBI + unprimed MSC groups were not statistically significantly different.
However, primed MSC after TBI improved the latency to the level of uninjured group.
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Figure 7 Examination of cells pre-transplantation and 2 days or 1 month post transplantation. (A) Viability of trans-retinoic acid (RA)-
primed CD133+ABCG2+CXCR4+ mesenchymal stem cells (MSC) held in either PBS or pluronic F-127 (PF-127) carrier for 2 hours prior to
implantation. Results represent the average +/- SD for viability of cells from 10 blood donors. Statistically significant comparisons (*P < 0.05) for
PBS compared to PF-127 as vehicle are indicated. (B) Schematic diagram showing site of implantation of MSC into the lateral ventricle (red
circle) of non-immunosuppressed male Sprague-Dawley rats. Arrow indicates the site of the fluid percussion traumatic brain injury (TBI). (C-H)
Confocal micrographs of 7-μm sections of brains. (C) Sections from uninjured rats sacrificed at 1 month showed that carboxyfluorescein
succinimidyl ester (CFSE)-labeled MSC (green) expressed CXCR4 (red). White arrows point to CFSE-labeled MSC. (D) Sections of brains of TBI rats
sacrificed 2 days after transplantation. CXCR-4+ CD133+ABCG2+CXCR4+ MSC are noted with white arrows. (E) Brain section 1 month after
transplantation (ventricle is indicated by the white *, white arrows identify migrated CFSE+ (green) MSC. (F) Higher magnification image of MSC
in the hippocampus of the TBI rat. (G) Some cells were elongated and expressed tyrosine hydroxylase (TH) (red) or (H) type III beta tubulin (Tuj1)
(red). (C-H) diamidino-2-phenylindole (DAPI) nuclear stain (blue).
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closer to the injury site (Figure 7E and 7F). Many MSC
were found in the hippocampus (Figure 7F) and cortex
(Figure 7G and 7H) and some of these cells expressed
TH (Figure 7G) as well as Tuj1 (Figure 7H).
In a subset of experiments non-CFSE-tagged MSC
were transplanted into rats used to evaluate induction of
apoptosis using the TUNEL assay. Examination of levels
of apoptosis at the injury site in these animals showed
that no apoptosis was seen in uninjured rats at 2 days
(Figure 8A), or at 1 month post transplant (Figure 8D).
In TBI animals, apoptotic nuclei could be seen in sec-
tions near the injury site at 2 days (Figure 8B) but few
apoptotic cells were seen in MSC-treated TBI animals
and staining for human MHC I showed the presence of
cells in this area (Figure 8C). Similar results were seen
at 1 month with many apoptotic nuclei present in
regions near the injury site with less apoptosis seen in
the in the TBI and MSC-treated group than in TBI ani-
mals that did not receive transplanted MSC (Figure 8E
and 8F).
Evaluation of MSC products in sections of brains har-
vested at 2 days post transplantation of CFSE-tagged
MSC in regions near the injury site showed production
of CSPG (Figure 8H), GFAP (Figure 8I) and BDNF (Fig-
ure 8J), which was seen for RA-primed MSC cultured
for 7 days in vitro but not in unprimed MSC (Figure
8G); evaluation also showed production of CSPG (Figure
8K and 8M) as well as BDNF(Figure 8M) in regions
near the injury site.
MSC survival, location and fate three months post
transplantation
Examination of cell survival after transplantation indi-
cated that 34% of cells transplanted into uninjured rats
survived until 3 months compared to 21% survival in
TBI rats (Figure 9A). Of the cells surviving transplanta-
tion, significantly more cells in the TBI rats were posi-
tive for expression of Tuj1 (87%) and NEUN (91%)
compared to expression of Tuj1 (41%) or NEUN (31%)
in uninjured rats (Figure 9A). The inter-observer agree-
ment for the cell counts in uninjured rats was 100% for
counts of CFSE+ cells, 99% for Tuj1 counts and 100%
for NEUN counts, and in TBI rats was 100% for counts
of CFSE+ cells, 100% for Tuj1 counts and 100% for
NEUN. A diagram of the injury site (Figure 9B) shows
the regions examined in Figure 9C-J. Morphology of the
CD133+ABCG2+CXCR4+ MSC engrafted in the brain
after 3 months included amoeboid, elongated or rod-
shaped cells (Figure 9C-H), as well as cells with more
complex morphology (Figure 9I and 9J). Many cells in
regions shown in Figure 8C were positive for expression
of Tuj1 (Figure 9D). Many elongated, TH-expressing
cells were found in the hippocampus (Figure 9F-H).
MHC I staining confirmed that the CFSE+ cells were
human in origin (Figure 9E and 9I). In some regions of
the hippocampus networks of MSC showed intercon-
nections between cells (Figure 9F-H) and many of the
cells in these clusters of MSC were shown to be TH-
positive (Figure 9G and 9H). A small portion of MSC
was positive for GFAP, an astrocyte marker, and had a
more complex morphology with multiple branched cell
processes (Figure 9J).
Discussion
Previous studies have shown the benefit of using MSC
for the treatment of ischemia or TBI in animal models
[18,4,6] but investigations to quantify MSC neural differ-
entiation efficiency have yet to be accomplished. In
order to realize the clinical benefits of MSC and other
stem cell types, consistent methods for MSC subpopula-
tion selection and higher efficiencies of differentiation
towards neural lineages need to be realized. Stem cells
generally require lineage priming in order to express
genes associated with commitment to specific differen-
tiation pathways. RA treatment has been used for prim-
ing embryonic [38] and adult stem cells for neuronal
marker induction, development of neuronal lineages
[25-28] and to promote survival, proliferation and neu-
rotropic responsiveness [27,28]. It is important to con-
sider that although priming has been shown to initiate
neurogenesis or neuronal marker induction, it does not
guarantee production of a specific neuronal lineage and
this remains a major hurdle to development of any
neural stem cell therapy.
In this study we were interested in assessing the
neural lineage potential of subpopulations of MSC that
could be capable of migrating to injury sites based on
the CXCR4/SDF-1 pathway. We focused our attention
on the isolation of HPBD MSC populations that co-
expressed immature stem cell markers CD133, as well
as ABCG2 or SSEA-4 combined with expression of
CXCR4.
MSC were isolated using centrifugal elutriation. We
then sorted the MSC based on expression of CD133, or
CD133 and ABCG2, or CD133 and ABCG2 and SSEA-4
combined with expression of CXCR4. We examined the
capability of each MSC subpopulation to express neuro-
nal markers following RA priming. Addition of expres-
sion of each subsequent marker used at the time of
isolation resulted in a stepwise increase in efficiency of
neuronal marker induction. However, the yield of cells
for each subpopulation as cell surface markers were
added was significantly reduced. One subpopulation of
CXCR4+CD133+ABCG2+SSEA-4+ MSC had the high-
est efficiency of neural marker induction as measured by
expression of nestin at 24 hours and TH by 7 days of
culture but we were not able to consistently isolate
enough of these cells to allow for extensive in vitro or
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Figure 8 Examination of induction of apoptosis. Brains were harvested at 2 days (A-C) or 1 month (D-F) and subjected to terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analysis. Representative images of sections taken from (A) uninjured animals, (B)
traumatic brain injury (TBI) animals and (C) TBI animals that received trans-retinoic acid (RA)-primed mesenchymal stem cells (MSC). Evaluation of
apoptosis induction one month following TBI is shown in (D) uninjured (E) TBI animals and (F) TBI animals that received RA-primed MSC. Insert
in E shows higher power image of TUNEL+ nuclei. Production of chondroitin sulfate proteoglycan (CSPG), glial fibrillary acidic protein (GFAP) or
brain derived neurotropic factor (BDNF) in (G) unprimed MSC and (H-J) RA-primed MSC cultured for 7 days in vitro. (H) Staining for expression of
CSPG (green) in cells not expressing GFAP (red) in RA-primed MSC. (I) Co-expression of CSPG (green) and GFAP (red) in some RA-primed MSC. (J)
Expression of BDNF (green) and GFAP (red) in RA-primed MSC. (K-M) Evaluation of CSPG and BDNF in RA-primed MSC in vivo following TBI. (K)
Evaluation of MSC products in sections of brains harvested at 2 days post transplantation of carboxyfluorescein succinimidyl ester (CFSE)-tagged
MSC in regions near the injury site, CFSE-positive MSC (green) and CSPG (red). (J) Cells positive for CSPG and diamidino-2-phenylindole (DAPI)
and (M) cells positive for CFSE (green) and BDNF (red) also seen in regions near the injury site. (A-M) DAPI nuclear stain (blue).
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Figure 9 Evaluation of mesenchymal stem cells (MSC) 3 months post transplantation. (A) Results represent the average +/- SD for cell
counts from brains of uninjured (n = 8) and traumatic brain injury (TBI) (n = 8) rats. Statistically significant comparisons (*P < 0.05) for expression
of type III beta tubulin (Tuj1) or neuron specific nuclear protein (NEUN) in brain sections from uninjured compared to TBI rats. (B) Diagram of
locations viewed in images B-I (red shaded circle) and location of site of fluid percussion injury (black arrow). (C) Brain section from TBI rats
sacrificed 3 months after transplantation of carboxyfluorescein succinimidyl ester (CFSE)+ CD133+ABCG2+CXCR4+ MSC showing cells in the
cortex and hippocampus near the injury site. White arrows indicate CFSE-positive MSC (green). (D) Image of area outlined in box of figure B,
CFSE (green) and Tuj1 (red). (E-J) Examination of transplanted MSC showed that most cells had elongated, CFSE (green), DAPI (blue). (E) These
cells were positive for expression of human major histocompatibility complex class I (MHC 1) (red). (F) CFSE+ cells in the hippocampus at 3
months had reduced levels of CXCR4 staining. (F and G) In some regions of the hippocampus, networks of MSC showed interconnections
between cells and many cells in these clusters were (G and H) tyrosine hydroxylase (TH)-positive. (I) Human MHC I expression by cells in J and
(J) a small portion of MSC were positive for expression of the astrocyte marker GFAP, and (H) had a more complex morphology with multiple
branched cell processes. (D-J) Diamidino-2-phenylindole (DAPI) nuclear stain (blue).
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in vivo study. It is because of this that we continued our
work using CD133+ABCG2+ CXCR4+ MSC. Although
isolation of adequate cell numbers for use as a therapy
is important, the efficiency with which MSC are able to
differentiate into specific lineages is perhaps the critical
factor when considering a cell population for use as a
cell-based therapy. In many disease processes, it is con-
ceivable that a small number of cells that efficiently dif-
ferentiate into a specific lineage and migrate to sites of
injury would be more effective than larger numbers of
less efficient cells. The evaluation of subpopulations
such as the ones described here form the basis for
exploring co-expression of other markers allowing for
enrichment of cell types that consistently differentiate
into specific neuronal lineages, which might prove to be
of greater therapeutic value.
This subpopulation of CD133+ABCG2+CXCR4+ MSC
required RA priming to initiate induction of early neu-
ronal markers nestin and MAP-1b, and later the expres-
sion of more mature neuronal markers such as TH and
GFAP. Neural lineage markers that were used to evalu-
ate the neural potential of subpopulations of CD133
+ABCG2+CXCR4+ MSC included nestin, MAP1-b, TH,
Tuj1, NEUN, GFAP, CHAT and GalC.
In our in vitro experiments CD133+ABCG2+CXCR4+
MSC consistently produced low percentages of cells
(< 10%) expressing neuronal markers such as CHAT,
GalC, GFAP but higher percentages of cells expressing
TH (45.2 +/- 9.7%), Tuj1 (35.23 +/- 7.9%) and NEUN
(28.2 +/- 11.1%). In vitro assays also showed that the
CD133+ABCG2+CXCR4+ subpopulation of cells iso-
lated from a variety of donors could be consistently
directed at high efficiency towards production of TH.
Similar results were observed when CD133+ABCG2
+CXCR4+ MSC were co-cultured with mature neuronal
lines in either mixed cultures that allowed for direct cell
contact, or a transwell system, which only allowed for
transfer of soluble factors (Figure 3). Co-culture of
CD133+ABCG2+CXCR4+ MSC with human astroglial
(SVGp12) cells induced high levels of expression of TH
as did co-culture with rat astrocyte (DITNC 1) cells and
dopaminanergic (SK-N-MC) cells (Figure 3). In all cases
of in vitro culture morphological and immunophenoty-
pic changes suggestive of neuronal differentiation
persisted over 7 days.
One striking feature of CD133+ABCG2+CXCR4+ MSC
in vitro differentiation was the speed of the response,
since within 12 hours (for most donor cells) and consis-
tently by 24 hours after priming, MSC assumed features
typical of neuronal morphology in both in vivo and in
vitro culture. It is our feeling that the faster the cells can
be isolated, primed and transplanted within 24 hours
after the injury the better, since early treatment could
limit damage to the brain, subsequent loss of neurons,
and allow MSC to participate in the healing process.
Our data also support the critical role played by the
CXCR4/SDF-1 pathway in migration of CD133+ABCG2
+CXCR4+ MSC towards regions of brain injury [20-22].
MSC migrated in vitro in response to SDF-1 and also
migrated in response to supernatants produced from the
homogenized brains of TBI rats but not uninjured rats
(Figure 4A). Loss of ability to migrate after dexametha-
sone treatment due to reduced expression of CXCR4 has
been previously described [39]. CD133+ABCG2+CXCR4
+ MSC treated with dexamethasone showed reduced
levels of CXCR4 and exhibited a significant reduction in
the chemo-attractant and transmigration effect of SDF-1
in vitro. These data suggest that dexamethasone might
decrease the migratory capability of MSC in vivo if given
during the acute phase of a TBI. Transplantation of
primed MSC into the brains of uninjured rats did not
result in high levels of migration and most cells remained
in the lateral ventricle one month after transplantation.
Primed CXCR4+MSC migrated to the injury site in TBI
rats and into regions also positive for SDF-1.
In order to evaluate the influence of the in vivo microen-
vironment or the atypical and potentially inhospitable
environment created by TBI on MSC graft survival, migra-
tion and differentiation, we transplanted MSC into the
brains of either uninjured or TBI rats. We delivered
human CD133+ABCG2+CXCR4+ MSC directly into the
lateral ventricle of rat brains 24 hours after fluid percus-
sion injury. This was done to take advantage of a brain
access point created by the current clinical practice of pla-
cing an intra-ventricular catheter in the lateral ventricle
for measuring intracranial pressure and therapeutically
removing cerebrospinal fluid in patients with moderate to
severe TBI. It is important to note that delivery of primed
MSC in a clinical setting could also be done through an
intraventricular route, thereby reducing the need to
directly place the stem cells at an injury site. We also uti-
lized this transplantation site so that MSC could use the
normal migratory pathway used by neuroblasts from the
subventricular zone (SVZ) traveling along the lateral ven-
tricles via the flow of CNS fluid [40], and be in a better
position to respond to the brain’s own injury-induced che-
mokine-assisted migration cues. This was also done
because evidence suggests that the cells of the SVZ pro-
vide an environment that normally promotes neurogenesis
[41].
Several studies have documented an acute injury per-
iod during which release of inflammatory factors is
extremely robust, creating a hostile environment for cell
engraftment and differentiation followed by a fall in the
release of injury response factors over time [42-46]. This
might be an explanation for those MSC that retained
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CXCR4 expression which, although they had migrated
to the injury site, remained quiescent with no sign of
morphologic indication of differentiation. Injured brains
of experimental animals in other studies receiving fluid
percussion TBI exhibited both primary as well as sec-
ondary (delayed) neuronal death for a prolonged period
after injury, and it has been shown that neural degenera-
tion occurs as early as 10 minutes after injury [45,32].
Analysis of rat brains 3 months after transplantation
of CD133+ABCG2+CXCR4+ MSC showed that many
cells had lost expression of CXCR4, differentiated and
produced Tuj1, TH as well as GFAP and NEUN. We
did find it interesting to note that although more CFSE
+ cells were found in uninjured animals at 3 months
than in TBI rats, far more cells in TBI rats were positive
for expression of Tuj1 (87% compared to 41%) and
NEUN (91 compared to 77%). Expression of Tuj1 is
indicative of immature neurons but not necessarily inte-
gration of MSC into the brain, but the expression of
NEUN indicates the presence of mature neurons that
integrated into the brain. Differences in the expression
of markers of neuronal maturation of the MSC in vivo
may be due to the site at which the cells engrafted, but
it is also important to consider that the influence of fac-
tors produced in response to the injury could potentially
override cues to differentiate in a site-specific manner.
Functional evaluation of the use of MSC treatment in
TBI animals to examine spatial memory performance
using the MWM showed that improvement was seen in
MSC-treated compared to untreated TBI rats. The effect
of TBI on MWM latency was practically significant
compared with the sham group. Primed MSC after TBI
considerably improved MWM latency compared with
the unprimed MSC group. However, those effects were
not statistically significant due to small numbers of ani-
mals in each group and large variability in the data.
Assuming the variability in the data and the mean dif-
ferences remain the same or remain similar, we would
have needed 10 to 11 animals per group to detect a dif-
ference at the 0.05 level of significance and a power of
80%. Isolation of adequate numbers of human stem cells
for transplantation limited the numbers of animals that
could be used in these experiments.
Despite the lack of maturation of the majority of large
numbers of MSC after transplantation, we did see
improvement in the cognitive ability of TBI rats over
the testing period, suggesting that neural primed MSC
may function as supportive cells in concert with endo-
genous stem cells from the hippocampus and SVZ of
the lateral ventricle in the reparative process.
MSC have been shown to have limited survival after
engraftment in the CNS of TBI rats [42,43]. In an
attempt to reduce graft cell loss following transplanta-
tion we chose to utilize the hydrogel Pluronic (PF)-127
as a cell transport vehicle. PF-127 forms a soft gel at
room temperature, making transplantation easier [47],
and several reports have documented the ability of PF-
127 to stabilize membranes [48-50]. These studies
demonstrated the potential for hydrogels as a clinically
feasible delivery system. Poloxamer hydrogels, such as
pluronic-188, have also been shown to reduce tissue
damage and macrophage infiltration in rats following
TBI, thus, reducing inflammation [50]. It is important to
note that although we did not use any immunosuppres-
sive therapy, nor irradiate human MSC prior to trans-
plantation, we did not see any signs of inflammation or
leukocyte infiltration into the brain tissue in sham, TBI
or MSC-treated rats.
The therapeutic effects of MSC following transplanta-
tion can also be due to inhibition of pathogenic immune
responses and release of neuroprotective factors [51-59]
or immunomodulatory molecules [52-55,57,59,60]. We
feel that the improvement in cognitive function, mea-
sured by the MWM demonstrated by TBI animals trea-
ted with RA-primed MSC in this study at early time
points, such as at 2 days, was not due to MSC replace-
ment of damaged cells at the injury site. Examination of
the results suggest that the early influence of the trans-
planted cells was more likely due to release of factors
such as CSPG, BDNF or other as yet undefined factors,
which may have helped to support damaged cells at the
injury site and reduce apoptosis. We did see some dif-
ferentiation of the transplanted cells as indicated by
Tuj1 or TH expression at 1 month, as well as GFAP
production, which is indicative of astrocyte formation at
3 months but the majority of transplanted cells did not
express mature neuronal markers at the 2-day time
point. Future studies will concentrate on evaluation of
MSC-derived immune or neuroprotective factors as well
as evaluation of factor production of MSC subsets.
Conclusions
In summary, the practical design of any stem cell-based
clinical therapy should include: (1) identification of cell
surface markers that allow for consistent isolation of
cells in sufficient numbers and purity for use in a ther-
apy; (2) differentiation at high efficiency to neural
lineages; (3) consideration of the ability of the cells to
migrate to damaged areas without the need for direct
transplantation at the site where the injury has occurred,
and (4) consideration of the ability of cells to produce
neuro-protective factors. In this study we provide
important information about the development of poten-
tial therapeutic strategies to enhance the clinical applic-
ability of MSC transplantation. We demonstrate here
that a population of human CD133+ABCG2+CXCR4+
MSC could be consistently isolated from nonmobilized
PB and induced to produce factors that support cell
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survival at early time points following transplantation,
and to differentiate along neural lineages after RA prim-
ing. Our findings have implications for the development
of clinical strategies to examine the effectiveness and
applicability of the use of PB-derived MSC for the treat-
ment of TBI or other neurodegenerative diseases. As
methods for identification and isolation of adult MSC
improve, the ability to uncover subpopulations whose
lineage determinants combined with priming strategies
target the production of a specific neuronal cell type,
cell population or neuro-protective factor production,
may enhance our ability to develop stem cell-based ther-
apeutics in the future.
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